Distinguished in Dowling-Meara Epidermolysis Bullosa Simplex

Malobi Ogboli

Birmingham Children's Hospital NHS FT
Birmingham, ENG, GB 
Distinguished in Dowling-Meara Epidermolysis Bullosa Simplex
Birmingham Children's Hospital NHS FT
Birmingham, ENG, GB 
OverviewLocationsClinical Research

Overview

Malobi Ogboli practices in Birmingham, United Kingdom. Ogboli is rated as a Distinguished expert by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. Their top areas of expertise are Junctional Epidermolysis Bullosa, Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, Dominant Dystrophic Epidermolysis Bullosa, and Gastrostomy.

Their clinical research consists of co-authoring 21 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Dowling-Meara Epidermolysis Bullosa Simplex.

Locations

Birmingham Children's Hospital NHS FT
Birmingham, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: July 20, 2023
Intervention Type: Drug
Study Drug: Oleogel-S10
Study Phase: Phase 3

21 Total Publications

Mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: MissionEB protocol for a randomised, double-blinded, placebo-controlled, two-centre, crossover trial with an internal phase I dose de-escalation phase and open-label extension.
Mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: MissionEB protocol for a randomised, double-blinded, placebo-controlled, two-centre, crossover trial with an internal phase I dose de-escalation phase and open-label extension.
Journal: BMJ open
Published: May 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ogboli's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile